Its second oncology candidate to enter clinical trials
Glenmark Pharmaceuticals announced that the USFDA cleared the company's Investigational New Drug (IND) application to initiate a Phase 1 study of GBR 1342, a humanized, bispecific monoclonal antibody (bsAb) being studied for the treatment of multiple myeloma in patients who have received prior therapies. GBR 1342 is designed to activate the patient's immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors. It is based on Glenmark's proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
